MetaDeq Diagnostics
Private Company
Funding information not available
Overview
MetaDeq Diagnostics is an early-stage diagnostics company targeting the massive and growing market for MASH (formerly NASH) and liver fibrosis detection. Its core innovation, HeparDx, is a blood-based test validated in a 250-patient prospective study, demonstrating >95% accuracy in diagnosing MASH against the biopsy gold standard. The company is positioned to capitalize on new ADA screening guidelines and the recent FDA approval of the first MASH drug, Rezdiffra, which creates a pressing need for non-invasive diagnostics for patient identification and treatment monitoring.
Technology Platform
Liquid biopsy blood test analyzing biomarkers correlated with liver histology (lobular inflammation, hepatocyte ballooning, fibrosis).
Opportunities
Risk Factors
Competitive Landscape
The non-invasive MASH diagnostic market is competitive, including blood-based biomarkers (e.g., FIB-4, ELF test, NIS4) and imaging technologies like vibration-controlled transient elastography (FibroScan) and MR Elastography. MetaDeq claims a competitive advantage with >95% accuracy from a single biomarker and published prospective data.